Copyright © 2010 Kim M. Hirshfield et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. A. C. Antoniou and D. F. Easton, “Models of genetic susceptibility to breast cancer,” Oncogene, vol. 25, no. 43, pp. 5898–5905, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
2. D. Ford, D. F. Easton, M. Stratton, et al., “Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families,” American Journal of Human Genetics, vol. 62, no. 3, pp. 676–689, 1998. View at Publisher · View at Google Scholar · View at Scopus
3. J. E. Garber and K. Offit, “Hereditary cancer predisposition syndromes,” Journal of Clinical Oncology, vol. 23, no. 2, pp. 276–292, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
4. A. R. Venkitaraman, “Functions of BRCA1 and BRCA2 in the biological response to DNA damage,” Journal of Cell Science, vol. 114, no. 20, pp. 3591–3598, 2001. View at Scopus
5. L. M. Starita, A. A. Horwitz, M.-C. Keogh, C. Ishioka, J. D. Parvin, and N. Chiba, “BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II,” Journal of Biological Chemistry, vol. 280, no. 26, pp. 24498–24505, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. M. S. Greenblatt, P. O. Chappuis, J. P. Bond, N. Hamel, and W. D. Foulkes, “TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution,” Cancer Research, vol. 61, no. 10, pp. 4092–4097, 2001. View at Scopus
7. R. Pilarski, “Cowden syndrome: a critical review of the clinical literature,” Journal of Genetic Counseling, vol. 18, no. 1, pp. 13–27, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
8. C. Eng, “Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis,” Annals of the New York Academy of Sciences, vol. 968, pp. 213–221, 2002. View at Scopus
9. J. I. Risinger, A. K. Hayes, A. Berchuck, and J. C. Barrett, “PTEN/MMAC1 mutations in endometrial cancers,” Cancer Research, vol. 57, no. 21, pp. 4736–4738, 1997. View at Scopus
10. I. U. Ali, “Gatekeeper for endometrium: the PTEN tumor suppressor gene,” Journal of the National Cancer Institute, vol. 92, no. 11, pp. 861–863, 2000. View at Scopus
11. W. Lim, N. Hearle, B. Shah, et al., “Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome,” British Journal of Cancer, vol. 89, no. 2, pp. 308–313, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. D. Malkin, F. P. Li, L. C. Strong, et al., “Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms,” Science, vol. 250, no. 4985, pp. 1233–1238, 1990. View at Scopus
13. H. Nevanlinna and J. Bartek, “The CHEK2 gene and inherited breast cancer susceptibility,” Oncogene, vol. 25, no. 43, pp. 5912–5919, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
14. D. L. Stredrick, M. Garcia-Closas, M. A. Pineda, et al., “The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer,” Human Mutation, vol. 27, no. 6, pp. 538–544, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
15. S. Seal, D. Thompson, A. Renwick, et al., “Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles,” Nature Genetics, vol. 38, no. 11, pp. 1239–1241, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
16. N. Rahman, S. Seal, D. Thompson, et al., “PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene,” Nature Genetics, vol. 39, no. 2, pp. 165–167, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
17. D. F. Easton and R. A. Eeles, “Genome-wide association studies in cancer,” Human Molecular Genetics, vol. 17, no. R2, pp. R109–R115, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
18. K. Hemminki, A. Försti, and J. L. Bermejo, “New cancer susceptibility loci: population and familial risks,” International Journal of Cancer, vol. 123, no. 7, pp. 1726–1729, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
19. K. Hemminki, J. Sundquist, and J. L. Bermejo, “How common is familial cancer?” Annals of Oncology, vol. 19, no. 1, pp. 163–167, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
20. P. D. P. Pharoah, A. C. Antoniou, D. F. Easton, and B. A. J. Ponder, “Polygenes, risk prediction, and targeted prevention of breast cancer,” The New England Journal of Medicine, vol. 358, no. 26, pp. 2796–2803, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
21. P. D. Pharoah, J. Tyrer, A. M. Dunning, D. F. Easton, and B. A. Ponder, “Association between common variation in 120 candidate genes and breast cancer risk,” PLoS Genetics, vol. 3, no. 3, article e42, 2007. View at Publisher · View at Google Scholar · View at PubMed
22. D. J. Hunter, P. Kraft, K. B. Jacobs, et al., “A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer,” Nature Genetics, vol. 39, no. 7, pp. 870–874, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
23. S. N. Stacey, A. Manolescu, P. Sulem, et al., “Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer,” Nature Genetics, vol. 40, no. 6, pp. 703–706, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
24. S. N. Stacey, A. Manolescu, P. Sulem, et al., “Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer,” Nature Genetics, vol. 39, no. 7, pp. 865–869, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
25. D. F. Easton, K. A. Pooley, A. M. Dunning, et al., “Genome-wide association study identifies novel breast cancer susceptibility loci,” Nature, vol. 447, no. 7148, pp. 1087–1093, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
26. M. Udler and P. D. P. Pharoah, “Germline genetic variation and breast cancer survival: prognostic and therapeutic implications,” Future Oncology, vol. 3, no. 5, pp. 491–495, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
27. H. Song, S. J. Ramus, S. K. Kjaer, et al., “Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study,” Human Molecular Genetics, vol. 18, no. 12, pp. 2297–2304, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. E. Y. Cho, Y.-L. Choi, J. J. Han, K.-M. Kim, and Y. L. Oh, “Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization,” Pathology International, vol. 58, no. 1, pp. 17–25, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
29. S. Elsheikh, A. R. Green, M. A. Aleskandarany, et al., “CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome,” Breast Cancer Research and Treatment, vol. 109, no. 2, pp. 325–335, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
30. E. Yu, Y. S. Ahn, S. J. Jang, et al., “Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers,” Breast Cancer Research and Treatment, vol. 101, no. 3, pp. 269–278, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. K. Stemke-Hale, A.M. Gonzalez-Angulo, A. Lluch, et al., “An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer,” Cancer Research, vol. 68, no. 15, pp. 6084–6091, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. M. Ollikainen, A. Gylling, M. Puputti, et al., “Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma,” International Journal of Cancer, vol. 121, no. 4, pp. 915–920, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
33. J. K. Habermann, J. Doering, S. Hautaniemi, et al., “The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome,” International Journal of Cancer, vol. 124, no. 7, pp. 1552–1564, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
34. J. Palacios, M. J. Robles-Frias, M. A. Castilla, M. A. Lopez-Garcia, and J. Benitez, “The molecular pathology of hereditary breast cancer,” Pathobiology, vol. 75, no. 2, pp. 85–94, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. R. Bhargava, J. Striebel, S. Beriwal, et al., “Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers,” International Journal of Clinical and Experimental Pathology, vol. 2, no. 5, pp. 444–455, 2009. View at Scopus
36. A. Spitale, P. Mazzola, D. Soldini, L. Mazzucchelli, and A. Bordoni, “Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland,” Annals of Oncology, vol. 20, no. 4, pp. 628–635, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
37. M. C. U. Cheang, D. Voduc, C. Bajdik, et al., “Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype,” Clinical Cancer Research, vol. 14, no. 5, pp. 1368–1376, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
38. F. Bertucci, P. Finetti, N. Cervera, et al., “How different are luminal A and basal breast cancers?” International Journal of Cancer, vol. 124, no. 6, pp. 1338–1348, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
39. T. Sorlie, C. M. Perou, R. Tibshirani, et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10869–10874, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
40. L. D. Wood, D. W. Parsons, S. Jones, et al., “The genomic landscapes of human breast and colorectal cancers,” Science, vol. 318, no. 5853, pp. 1108–1113, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. S. H. Nordgard, F. E. Johansen, G. I. Alnaes, and B. Naume, “Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes,” Breast Cancer Research, vol. 9, no. 6, p. 113, 2007. View at Scopus
42. G. L. Bond, W. Hu, E. E. Bond, et al., “A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans,” Cell, vol. 119, no. 5, pp. 591–602, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
43. G. L. Bond, K. M. Hirshfield, T. Kirchhoff, et al., “MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner,” Cancer Research, vol. 66, no. 10, pp. 5104–5110, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
44. J. P. A. Ioannidis, G. Thomas, and M. J. Daly, “Validating, augmenting and refining genome-wide association signals,” Nature Reviews Genetics, vol. 10, no. 5, pp. 318–329, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
45. G. Thomas, K. B. Jacobs, M. Yeager, et al., “Multiple loci identified in a genome-wide association study of prostate cancer,” Nature Genetics, vol. 40, no. 3, pp. 310–315, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
46. C. I. Amos, X. Wu, P. Broderick, et al., “Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1,” Nature Genetics, vol. 40, no. 5, pp. 616–622, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
47. R. J. Hung, J. D. McKay, V. Gaborieau, et al., “A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25,” Nature, vol. 452, no. 7187, pp. 633–637, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
48. K. M. Brown, S. MacGregor, G. W. Montgomery, et al., “Common sequence variants on 20q11.22 confer melanoma susceptibility,” Nature Genetics, vol. 40, no. 7, pp. 838–840, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
49. P. Broderick, L. Carvajal-Carmona, A. M. Pittman, et al., “A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk,” Nature Genetics, vol. 39, no. 11, pp. 1315–1317, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
50. I. P. M. Tomlinson, E. Webb, L. Carvajal-Carmona, et al., “A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3,” Nature Genetics, vol. 40, no. 5, pp. 623–630, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
51. A. Tenesa, S. M. Farrington, J. G. D. Prendergast, et al., “Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21,” Nature Genetics, vol. 40, no. 5, pp. 631–637, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
52. T. Terzian, Y. Wang, C. S. Van Pelt, N. F. Box, E. L. Travis, and G. Lozano, “Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development,” Molecular and Cellular Biology, vol. 27, no. 15, pp. 5479–5485, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
53. J. M. Parant and G. Lozano, “Disrupting TP53 in mouse models of human cancers,” Human Mutation, vol. 21, no. 3, pp. 321–326, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
54. G. S. Atwal, G. L. Bond, S. Metsuyanim, et al., “Haplotype structure and selection of the MDM2 oncogene in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 11, pp. 4524–4529, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
55. G. S. Atwal, T. Kirchhoff, E. E. Bond, et al., “Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 25, pp. 10236–10241, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
56. D. Kulkarni, A. Vazquez, B. G. Haffty, et al., “A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer,” Carcinogenesis, vol. 30, no. 11, pp. 1910–1915, 2009.
57. H. Shi, S.-j. Tan, H. Zhong, et al., “Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia,” American Journal of Human Genetics, vol. 84, no. 4, pp. 534–541, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
58. P. Dumont, J. I.-J. Leu, A. C. Della Pietra III, D. L. George, and M. Murphy, “The codon 72 polymorphic variants of p53 have markedly different apoptotic potential,” Nature Genetics, vol. 33, no. 3, pp. 357–365, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
59. P. Sansone, G. Storci, S. Pandolfi, L. Montanaro, P. Chieco, and M. Bonafe, “The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia,” British Journal of Cancer, vol. 96, no. 8, pp. 1302–1308, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
60. M. Siddique and K. Sabapathy, “Trp53-dependent DNA-repair is affected by the codon 72 polymorphism,” Oncogene, vol. 25, no. 25, pp. 3489–3500, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
61. M. Thomas, A. Kalita, S. Labrecque, D. Pim, L. Banks, and G. Matlashewski, “Two polymorphic variants of wild-type p53 differ biochemically and biologically,” Molecular and Cellular Biology, vol. 19, no. 2, pp. 1092–1100, 1999. View at Scopus
62. H.-J. Kang, Z. Feng, Y. Sun, et al., “Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 24, pp. 9761–9766, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
63. W. Hu, Z. Feng, A. K. Teresky, and A. J. Levine, “p53 regulates maternal reproduction through LIF,” Nature, vol. 450, no. 7170, pp. 721–724, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
64. K. E. Nichols, D. Malkin, J. E. Garber, J. F. Fraumeni Jr., and F. P. Li, “Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 2, pp. 83–87, 2001. View at Scopus
65. A. Chompret, L. Brugieres, M. Ronsin, et al., “P53 germline mutations in childhood cancers and cancer risk for carrier individuals,” British Journal of Cancer, vol. 82, no. 12, pp. 1932–1937, 2000. View at Scopus
66. M. W. G. Ruijs, M. K. Schmidt, H. Nevanlinna, et al., “The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes,” European Journal of Human Genetics, vol. 15, no. 1, pp. 110–114, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
67. U. Tabori, S. Nanda, H. Druker, J. Lees, and D. Malkin, “Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome,” Cancer Research, vol. 67, no. 4, pp. 1415–1418, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
68. G. Bougeard, S. Baert-Desurmont, I. Tournier, et al., “Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome,” Journal of Medical Genetics, vol. 43, no. 6, pp. 531–533, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
69. D. van Heemst, S. P. Mooijaart, M. Beekman, et al., “Variation in the human TP53 gene affects old age survival and cancer mortality,” Experimental Gerontology, vol. 40, no. 1-2, pp. 11–15, 2005. View at Publisher · View at Google Scholar · View at Scopus
70. Z. Feng, W. Hu, A. K. Teresky, E. Hernando, C. Cordon-Cardo, and A. J. Levine, “Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 42, pp. 16633–16638, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
71. X. Xiong, M. Wang, L. Wang, et al., “Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia,” Leukemia Research, vol. 33, no. 11, pp. 1454–1458, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
72. E. F. Firoz, M. Warycha, J. Zakrzewski, et al., “Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma,” Clinical Cancer Research, vol. 15, no. 7, pp. 2573–2580, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
73. M. Nakashima, S. Kondo, Y. Shimizu, et al., “Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma,” Acta Oto-Laryngologica, vol. 128, no. 7, pp. 808–813, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
74. S. Hamid, Y.-H. Yang, K. N. L. Peng, et al., “MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset,” Oral Oncology, vol. 45, no. 6, pp. 496–500, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
75. N. Ohmiya, A. Taguchi, N. Mabuchi, et al., “MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis,” Journal of Clinical Oncology, vol. 24, no. 27, pp. 4434–4440, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
76. C. Menin, M. C. Scaini, G. L. De Salvo, et al., “Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status,” Journal of the National Cancer Institute, vol. 98, no. 4, pp. 285–288, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
77. G. L. Bond, C. Menin, R. Bertorelle, P. Alhopuro, L. A. Aaltonen, and A. J. Levine, “MDM2 SNP309 accelerates colorectal tumour formation in women,” Journal of Medical Genetics, vol. 43, no. 12, pp. 950–952, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
78. H. Lind, S. Zienolddiny, P. O. Ekstrom, V. Skaug, and A. Haugen, “Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer,” International Journal of Cancer, vol. 119, no. 3, pp. 718–721, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
79. G. Liu, P. Wheatley-Price, W. Zhou, et al., “Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk,” International Journal of Cancer, vol. 122, no. 4, pp. 915–918, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
80. X. Zhang, X. Miao, Y. Guo, et al., “Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer,” Human Mutation, vol. 27, no. 1, pp. 110–117, 2006. View at Publisher · View at Google Scholar · View at Scopus
81. K. Terry, M. McGrath, I.-M. Lee, J. Buring, and I. De Vivo, “MDM2 SNP309 is associated with endometrial cancer risk,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 4, pp. 983–986, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
82. M. Ueda, M. Yamamoto, O. Nunobiki, et al., “Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer,” Human Cell, vol. 22, no. 2, pp. 49–54, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
83. M. Sanchez-Carbayo, N. D. Socci, T. Kirchoff, et al., “A polymorphismin HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer,” Clinical Cancer Research, vol. 13, no. 11, pp. 3215–3220, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
84. Y. Horikawa, J. Nadaoka, M. Saito, et al., “Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder,” Oncology Reports, vol. 20, no. 1, pp. 49–55, 2008. View at Scopus
85. R. G. Khatri, K. Navaratne, and R. J. Weil, “The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme: laboratory investigation,” Journal of Neurosurgery, vol. 109, no. 5, pp. 842–848, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
86. S. Cattelani, R. Defferrari, S. Marsilio, et al., “Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients,” Clinical Cancer Research, vol. 14, no. 11, pp. 3248–3253, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
87. F. Bartel, J. Jung, A. Bohnke, et al., “Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival,” Clinical Cancer Research, vol. 14, no. 1, pp. 89–96, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
88. S. Wilkening, J. L. Bermejo, and K. Hemminki, “MDM2 SNP309 and cancer risk: a combined analysis,” Carcinogenesis, vol. 28, no. 11, pp. 2262–2267, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
89. Z. Hu, G. Jin, L. Wang, F. Chen, X. Wang, and H. Shen, “MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 12, pp. 2717–2723, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus